The current situation of escalating costs for these orphan drugs would tend to indicate that prices of some drugs may be reaching a breaking point.
Generex Biotechnology plans to buy 51% share of Emmaus Life Sciences, the company that recently submitted an NDA for L-glutamine to treat sickle cell disease.
Last November, KaloBios was THE company to follow when biotech bad boy Martin Shkreli purchased stock in the struggling company and named himself the CEO.
Savara Pharmaceuticals has acquired the assets of Serendex Pharmaceuticals to develop drugs to treat pulmonary alveolar proteinosis, diffuse alveolar hemorrhae, and cystic fibrosis.
With QLT, there is only 1 orphan drug in development and to give you some perspective on how poorly Aegerion’s 2 approved drugs are doing in the marketplace, QLT is the one buying Aegerion.
It has been a busy week for the rare disease community. Below are the 5 topics that has grabbed our attention this week.
The former biotech CEO referred to as “The Most Hated Man in America” was in court today for his upcoming trial for fraud.
Earlier this week, we reported on interest that Shire was showing in Baxalta. Now, Baxalta stock is plunging almost 30% as reports state there are potential tax-related hurdles in its acquisitions by Shire.
KaloBios Pharmaceuticals announced it has filed for a Chapter 11 bankruptcy in the United States Bankruptcy Court for the District of Delaware (Case No. 15-12628).
If it weren’t for bad news, KaloBios would have no news at all.
$vacMongoViewPlus$ $vAR$